On October 11, 2023 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard to treat tumors and viruses, reported that Walter Klemp, President and Chief Executive Officer and Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin, will participate at the Virtual Investor Ask the CEO Conference on Tuesday, October 24, 2023 at 12:00 PM ET (Press release, Moleculin, OCT 11, 2023, View Source [SID1234635854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The "Ask the CEO" conference is intended to provide the investment community with access to ask their questions directly to management. Investors and interested parties will have the opportunity to submit questions live during the event. Questions can also be pre-submitted leading up to the event through virtualinvestorco.com/asktheceo-mbrx. Participating companies will answer as many questions as possible during the event.

A live video webcast of the event will be available on the Events page of the Investors section of the Company’s website (moleculin.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

On October 11, 2023 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported that its President and CEO, Robert E. Hoffman will present at the 8th Annual Dawson James Small Cap Growth Conference on Thursday, October 12, 2023 at 10:30 am ET (Press release, Kintara Therapeutics, OCT 11, 2023, View Source [SID1234635853]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 11, 2023 ErVaccine Technologies (now ErVimmune), a French biotechnology company developing therapeutic vaccines and cellular immunotherapies targeting unconventional tumor antigens, reported a sponsored research agreement with Servier that will leverage ErVimmune’s expertise and proprietary platforms to discover biomarkers of response to therapies under development by Servier (Press release, ErVaccine, OCT 11, 2023, View Source [SID1234635852]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to have established a research collaboration with Servier who has a proven track record in oncology," said Stéphane Depil, MD, PhD, founder and Executive Chairman of ErVimmune. "Together we will evaluate the impact of modulating a new cancer target on the expression of specific endogenous retroviruses with the aim of discovering novel therapeutic approaches in the field of cancer immunotherapy. Servier, with their deep and integrated capabilities throughout the entire pharmaceutical R&D chain, is an ideal partner for ErVimmune in this development."

"ErVimmune has a unique platform for the identification and validation of unconventional tumor epitopes. The strong synergies between the Servier research team and ErVimmune’s expertise will allow us to exploit new mechanisms for cancer immunotherapies with the potential to change the cancer treatment landscape
as we know it today," said Don Simons, PhD, Head of U.S. Pharmacology at Servier.

Under the terms of the agreement Servier will fund research efforts to discover endogenous retrovirus- derived biomarkers and investigate mechanisms that regulate expression of ErVimmune’s proprietary cancer vaccine targets.

On October 6, 2023 Defence Therapeutics Inc. ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, reported its participation to the upcoming Festival of Biologics to be held in Basel, Switzerland, October 10-12, 2023 (Press release, Defence Therapeutics, OCT 6, 2023, View Source;utm_medium=rss&utm_campaign=defence-to-present-three-of-its-leading-products-at-the-upcoming-festival-of-biologics-in-basel-switzerland [SID1234635851]).

The Festival of Biologics is a hub for the life science community to bridge the gap between academia and industry, covering the start to finish of biologics from discovery, through development, to manufacturing, clinical trials and commercialisation. Biologics have completely transformed the way that patients are treated. Biologics are central as they increase the range of options for treatments, giving new opportunities for patients and their clinicians.

With five events in one, the Festival of Biologics encourages conversation across the entire industry to inspire changes, bring forward innovations, and address complex challenges that the biologics industry is facing. In addition, this meeting offers an unparalleled opportunity to hear from stakeholders representing both the science and business communities who report on the latest data impacting cancer therapeutics to fight a wider range of cancers. The Festival of Biologics emphasizes the future needs of the oncology industry and highlights the importance for novel modalities related to cell therapies, vaccines and more effective antibody-drug conjugates (ADCs).

Defence is pleased to present its latest data during the Festival of Biologics on three of its leading products: i) its ARMTM anti-cancer vaccine technology, ii) its anti-cervical protein-based AccuVAC-PT007 vaccine and iii) its advanced AccuTOXTM program as an injectable for solid tumors.

"The three presentations given by our Chief Scientific Officer, Dr. Moutih Rafei, are aimed at two main objectives: i) to share with the scientific community how our innovative Accum platform technology can uplift many weak or moderate biomedical treatments as a means to significantly enhance their therapeutic window of action, and ii) to establish strategic partnerships with major players in the field to accelerate our therapeutics to patients faster", says Mr. Plouffe, CEO and president of Defence.

In addition, Defence has granted incentive stock options to its directors and management to purchase a total of 2,400,000 common shares of Defence pursuant to and in accordance with the terms and conditions of Defence’s stock option plan, subject to any regulatory approval. Each stock option vests immediately and is exercisable at a price of $2.50 per share for a period of ten years from the granted date.

On October 11, 2023 Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class, dual-acting targeted tumor immunotherapy, reported positive initial data from Part 2 of its Phase 1/2a CICILIA basket trial with all trial endpoints met (Press release, Cytovation, OCT 11, 2023, View Source;utm_medium=rss&utm_campaign=cytovation-reports-promising-interim-results-from-phase-1-2a-cicilia-study-with-cypep-1-in-solid-tumors [SID1234635850]). In this heavily pretreated, advanced and metastatic patient group CyPep-1 exhibits an excellent safety profile with no dose-limiting toxicities and has shown strong early signs of efficacy across solid tumor types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lars Prestegarden, MD, PhD, CEO of Cytovation, commented: "The initial efficacy data from our CICILIA basket trial are highly encouraging and important to informing our view of the future development pathway for CyPep-1. They confirm our pre-clinical findings suggesting that CyPep-1’s unique, dual mechanism of action could offer an important treatment option for patients whose tumors are driven by an aberrant Wnt/β-catenin signaling pathway, which is estimated to drive up to 20% of all solid tumors and can be as high as 90% in certain types. Our fast-to-market strategy in Adrenocortical Carcinoma is intended to provide us with a bridgehead from which to rapidly expand development of CyPep-1 into other beta-catenin-driven indications, like Colorectal and Liver Cancer, bringing a potentially important new treatment option to significant numbers of patients." The early signals of efficacy from CICILIA confirm the importance of CyPep-1’s unique dual mechanism of action with the most promising responses seen in patients with tumor types characterized by aberrant Wnt/β-catenin pathway signaling and with liver metastases. This is consistent with pre-clinical findings, further details of which will be presented at the upcoming European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) congress (October 20th – 23rd). Furthermore, these pre-clinical and early clinical findings support the Company’s decision to rapidly advance development of CyPep-1 with an initial focus on metastatic Adrenocortical Carcinoma (ACC), a rare and highly aggressive tumor type driven by Wnt/ β-catenin and with no approved treatment options after first line. Cytovation is planning to start a Phase 2 trial in ACC in 2024 with registrational intent. This strategy provides a fast and cost-effective route to market, while validating the broader potential of the CyPep-1 platform for future development indications in β-catenin-driven solid tumors.

About CyPep-1
CyPep-1 is a unique and highly differentiated synthetic peptide therapy that has the potential to change the outlook for large cancer patient populations where there remains an urgent need for new treatment options. CyPep-1 has a unique dual mechanism of action, combining inhibition of the Wnt/β-catenin oncogenic pathway with tumor-specific cell destruction and immune activation through neoantigen release and in situ vaccination. Preclinical and early clinical findings have demonstrated that CyPep-1 is safe and well tolerated with no dose-limiting toxicities and strong signs of biological activity and clinically relevant responses.